Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Financing Activities (2020 - 2025)

Mirum Pharmaceuticals has reported Cash from Financing Activities over the past 6 years, most recently at $9.0 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $9.0 million for Q4 2025, up 68.52% from a year ago — trailing twelve months through Dec 2025 was $40.1 million (up 126.8% YoY), and the annual figure for FY2025 was $40.1 million, up 126.8%.
  • Cash from Financing Activities for Q4 2025 was $9.0 million at Mirum Pharmaceuticals, down from $16.1 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for MIRM hit a ceiling of $207.1 million in Q3 2023 and a floor of -$329000.0 in Q4 2022.
  • Median Cash from Financing Activities over the past 5 years was $6.9 million (2021), compared with a mean of $28.8 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 263548.0% in 2021 and later plummeted 153.5% in 2022.
  • Mirum Pharmaceuticals' Cash from Financing Activities stood at $615000.0 in 2021, then plummeted by 153.5% to -$329000.0 in 2022, then skyrocketed by 640.12% to $1.8 million in 2023, then surged by 200.51% to $5.3 million in 2024, then soared by 68.52% to $9.0 million in 2025.
  • The last three reported values for Cash from Financing Activities were $9.0 million (Q4 2025), $16.1 million (Q3 2025), and $8.7 million (Q2 2025) per Business Quant data.